CNGB3-Achromatopsia Clinical Trial With CNTF: Diminished Rod Pathway Responses With No Evidence of Improvement in Cone Function.
Department of Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin, United States;
Christopher
C
Langlo
Moorfields Eye Hospital, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom;
Adam
A
Dubis
Moorfields Eye Hospital, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom;
Michel
M
Michaelides
Department of Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin, United States; Department of Ophthalmology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States; and Department of Biophysics, Medical College of Wisconsin, Milwaukee, Wisconsin, United States.
Joseph
J
Carroll
D020934:Ciliary Neurotrophic Factor / Q000008:administration & dosage*; D003117:Color Vision Defects / Q000188:drug therapy*; D054815:Cyclic Nucleotide-Gated Cation Channels / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D017948:Retinal Rod Photoreceptor Cells / Q000502:physiology*
D020934:Ciliary Neurotrophic Factor; D054815:Cyclic Nucleotide-Gated Cation Channels